CBUS Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -3951.71% compared to Cibus, Inc.'s net margin of --. Cibus, Inc.'s return on equity of -150.36% beat CEL-SCI Corp.'s return on equity of -266.61%.

Cibus, Inc. has a consensus price target of $14.40, signalling upside risk potential of 794.41%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 568.24%. Given that Cibus, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Cibus, Inc. is more attractive than CEL-SCI Corp..

Cibus, Inc. has a beta of 1.626, which suggesting that the stock is 62.607% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Cibus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cibus, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Cibus, Inc. quarterly revenues are $615K, which are larger than CEL-SCI Corp. quarterly revenues of --. Cibus, Inc.'s net income of -$24.3M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Cibus, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cibus, Inc. is 16.71x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -3951.71% compared to Cibus, Inc.'s net margin of -953.4%. Cibus, Inc.'s return on equity of -150.36% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Cibus, Inc. has a consensus price target of $14.40, signalling upside risk potential of 794.41%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1014.47%. Given that IGC Pharma, Inc. has higher upside potential than Cibus, Inc., analysts believe IGC Pharma, Inc. is more attractive than Cibus, Inc..

Cibus, Inc. has a beta of 1.626, which suggesting that the stock is 62.607% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Cibus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cibus, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Cibus, Inc. quarterly revenues are $615K, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Cibus, Inc.'s net income of -$24.3M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Cibus, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cibus, Inc. is 16.71x versus 26.09x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -3951.71% compared to Cibus, Inc.'s net margin of -255.85%. Cibus, Inc.'s return on equity of -150.36% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Cibus, Inc. has a consensus price target of $14.40, signalling upside risk potential of 794.41%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -69.64%. Given that Cibus, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cibus, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Cibus, Inc. has a beta of 1.626, which suggesting that the stock is 62.607% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Cibus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cibus, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cibus, Inc. quarterly revenues are $615K, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cibus, Inc.'s net income of -$24.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cibus, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cibus, Inc. is 16.71x versus 5.44x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phio Pharmaceuticals Corp. has a net margin of -3951.71% compared to Cibus, Inc.'s net margin of --. Cibus, Inc.'s return on equity of -150.36% beat Phio Pharmaceuticals Corp.'s return on equity of -95.19%.

Cibus, Inc. has a consensus price target of $14.40, signalling upside risk potential of 794.41%. On the other hand Phio Pharmaceuticals Corp. has an analysts' consensus of $14.00 which suggests that it could grow by 1150%. Given that Phio Pharmaceuticals Corp. has higher upside potential than Cibus, Inc., analysts believe Phio Pharmaceuticals Corp. is more attractive than Cibus, Inc..

Cibus, Inc. has a beta of 1.626, which suggesting that the stock is 62.607% more volatile than S&P 500. In comparison Phio Pharmaceuticals Corp. has a beta of 0.920, suggesting its less volatile than the S&P 500 by 7.968%.

Cibus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phio Pharmaceuticals Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cibus, Inc. pays -- of its earnings as a dividend. Phio Pharmaceuticals Corp. pays out -- of its earnings as a dividend.

Cibus, Inc. quarterly revenues are $615K, which are larger than Phio Pharmaceuticals Corp. quarterly revenues of --. Cibus, Inc.'s net income of -$24.3M is lower than Phio Pharmaceuticals Corp.'s net income of -$2.4M. Notably, Cibus, Inc.'s price-to-earnings ratio is -- while Phio Pharmaceuticals Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cibus, Inc. is 16.71x versus -- for Phio Pharmaceuticals Corp.. Usually stocks with elevated PS ratios are considered overvalued.